Pediatric lymphoma is common in sub-Saharan Africa, where survival estimates are often based on limited follow-up with incomplete retention, introducing potential for bias. We compared 
INTRODUCTION
Lymphoma is the commonest pediatric cancer in sub-Saharan Africa (SSA). 1, 2 Long-term survival of >90% is achievable in developed countries, 3, 4 but outcomes are worse in SSA. 5, 6 Moreover, survival estimates from SSA are often limited by short observation times and loss to follow-up (LTFU). This is problematic, since patients contribute follow-up time in survival analyses until LTFU, with deaths being unascertained when patients are no longer under observation. This poses particular challenges in SSA, where retaining patients is difficult, deaths often occur at home, and vital registries are absent.
In human immunodeficiency virus (HIV) literature from the region, bias introduced by LTFU repeatedly leads to underestimated mortality, since death is a frequent cause of LTFU. 7, 8 In SSA cancer populations, similar findings have been noted for HIV-associated Kaposi sarcoma. 9, 10 For pediatric lymphoma, LTFU can occur among children who are deceased or cured. If the former is more common, LTFU would underestimate mortality similar to regional HIV literature. If the latter is more common, with families reluctant to spend time and effort to return for follow-up when intervention is no longer required, mortality could be overestimated. Since bias introduced by LTFU has not Abbreviations: BL, Burkitt lymphoma; CI, confidence interval; HIV, human immunodeficiency virus; HL, Hodgkin lymphoma; IQR, interquartile range; LTFU, loss to follow-up; OS, overall survival; SSA, sub-Saharan Africa been evaluated for pediatric lymphoma in SSA, we sought to quantify this within a prospective pediatric lymphoma cohort in Lilongwe.
RESULTS
We studied children <18 years of age with newly diagnosed lymphoma between June 1, 2013 and March 31, 2016 enrolled in a prospective observational cohort. 5, 11 Kaplan-Meier methods were used to estimate the overall survival (OS) from enrollment until death, LTFU, or administrative censoring on June 30, 2016. OS differences were assessed using the log-rank test.
Children were seen at each chemotherapy visit during active treatment, every 3 months after treatment completion for up to 2 years, and for any interim illness. Transportation reimbursement was provided to promote retention. For missed visits during active treatment, and monthly after treatment completion, cellphone contact was attempted by nonmedical study staff using up to three cellphone numbers provided by the guardian at the time of informed consent for study participation. During phone contact, the navigator determined vital status, health status, and encouraged the family to return to clinic with a reminder that transportation costs would be reimbursed. If cellphone contact was unsuccessful on three consecutive attempts, physical tracing was attempted using the home address provided by the guardian at between LTFU during or after treatment. To assess potential bias, we compared observation times and OS estimates using two approaches.
In passive follow-up, patients were considered lost to follow-up at the last clinic visit. For active follow-up, analyses were repeated with inclusion of data generated by cellphone and physical tracing. During the study period, 121 children were enrolled with lymphoma, all of whom were included in these analyses. Of these, 100 (83%) had Burkitt lymphoma (BL) and 21 (27%) Hodgkin lymphoma (HL), the two commonest pediatric lymphoma subtypes in SSA. However, we acknowledge that less frequent non-Hodgkin lymphoma subtypes might be diagnosed locally as BL given limited immunohistochemistry and absent molecular diagnostic tools, despite major efforts by our group to improve diagnostic pathology in Lilongwe. 12, 13 Baseline characteristics are shown in Table 1 
DISCUSSION
We evaluated bias in OS estimates introduced by LTFU in a prospective pediatric lymphoma cohort in Malawi by comparing results from passive versus active follow-up. With active tracing, median follow-up times increased and OS estimates were corrected downward. Differences between passive and active follow-up were greater for BL than for HL, with passive follow-up leading to many unascertained deaths.
There are various approaches to address bias from LTFU in resource-limited settings, where retaining patients in longitudinal studies is difficult. One approach is to exclude LTFU cases from survival analyses, but this may increase bias if LTFU is not independent of the risk of death. [14] [15] [16] Another approach is to assume all patients with LTFU have died. 14 
